Market Research > Industries > Healthcare

Market Research: Nonprescription Drugs Canada 2004

Nonprescription Drugs Canada 2004

Published April 2005

View PDF brochure

This study provides an in-depth analysis of Canada's nonprescription drug industry for 2004, including 26 product categories and profiles of 15 major and 20 minor over-the-counter drug manufacturers. The report provides information on sales and market share of leading brands and private-label products, advertising and promotional activity, retail distribution, regulatory activity, competition from alternative medicines, new product activity, and five-year forecasts. (Y228F)

	ORDER ONLINE

You may submit an online request to subscribe to sections of this report, using a simple three-step process. After submitting your online request, you will then be contacted by a member of our global sales team to confirm the final price, and complete the transaction. Upon acceptance of your order, we will deliver the files in pdf format via email.

STEP 1 of 3

– Select the sections in which you are interested by clicking on the appropriate boxes:

FULL REPORT [US$ 22 500 (twenty two thousand five hundred US Dollars)]

INDUSTRY ANALYSIS [US$ 4 500]

OVERALL MARKET AND TRENDS [US$ 2 700]

Table 2-1 MANUFACTURERS’ SALES OF NONPRESCRIPTION DRUGS BY VALUE, 2003 AND 2004
Table 2-2 RATE OF GROWTH FOR NONPRESCRIPTION DRUG CATEGORIES, 2003 TO 2004
Table 2-3 MANUFACTURERS’ SALES OF NONPRESCRIPTION DRUGS BY RETAIL OUTLET, 2004
Table 2-4 MANUFACTURERS’ SALES OF NONPRESCRIPTION DRUGS BY RETAIL OUTLET, 2004 CN
Table 2-5 MANUFACTURERS’ SALES OF PRIVATE-LABEL NONPRESCRIPTION DRUGS BY PRODUCT CATEGORY, 2004
Table 2-6 PRIVATE-LABEL SALES OF NONPRESCRIPTION DRUGS AS A PERCENTAGE OF CATEGORY SALES, 2004
Table 2-7 HISTORICAL MANUFACTURERS’ SALES AND GROWTH RATES IN THE NONPRESCRIPTION DRUG INDUSTRY BY PRODUCT CATEGORY, 1999 TO 2004
Table 2-8 HISTORICAL AND FORECAST GROWTH OF THE NONPRESCRIPTION DRUG INDUSTRY
Table 2-9 FORECAST MANUFACTURERS’ SALES OF NONPRESCRIPTION DRUGS BY PRODUCT CATEGORY, 2004 AND 2009
Table 2-10 FORECAST MANUFACTURERS’ SALES GROWTH OF NONPRESCRIPTION DRUGS BY PRODUCT CATEGORY, 2004 TO 2009

COMPETITIVE MARKET STRUCTURE [US$ 2 700]

Table 2-11 TOP 10 SUPPLIERS OF NONPRESCRIPTION DRUGS IN CANADA, 2004
Table 2-13 PERCENTAGE OF TOTAL SALES BY PRODUCT CLASS FOR THE TOP 15 SUPPLIERS OF NONPRESCRIPTION DRUGS IN CANADA, 2004
Table 2-15 FORECAST MANUFACTURERS’ SALES FOR THE TOP 15 SUPPLIERS OF NONPRESCRIPTION DRUGS IN CANADA, 2004 TO 2009
Table 2-16 FORECAST MANUFACTURERS’ SALES FOR THE TOP 15 SUPPLIERS OF NONPRESCRIPTION DRUGS IN CANADA, RANKED BY RATE OF GROWTH, 2004 TO 2009
Table 2-12 MANUFACTURERS’ SALES OF THE LEADING NONPRESCRIPTION DRUG SUPPLIERS TO CANADA BY PRODUCT CLASS, 2004
Table 2 14 CORPORATE OPERATING RESULTS OF 13 MAJOR MARKETERS OF NONPRESCRIPTION DRUGS IN CANADA, 1999 AND 2004

PRODUCTS [US$ 6 750]

OVERVIEW [US$ 1 700]

Figure 3A-1 MANUFACTURERS’ SALES OF PRODUCTS BY CLASS, 2004
Table 3A-1 MANUFACTURERS’ SALES OF NONPRESCRIPTION DRUGS BY PRODUCT CATEGORY, 2003 AND 2004

COUGH AND COLD PREPARATIONS [US$ 1 700]

Table 3B-1 MANUFACTURERS’ SALES OF COUGH AND COLD PREPARATIONS, 2003 AND 2004
Figure 3B-1 MANUFACTURERS’ SALES OF COUGH AND COLD REMEDIES, 2004

ALLERGY RELIEF PRODUCTS [US$ 350]

Table 3B-2 NEW ALLERGY RELIEF PRODUCTS INTRODUCED IN 2003 AND 2004
Table 3B 3 MANUFACTURERS’ SALES OF ALLERGY RELIEF PRODUCTS BY BRAND, 2003 AND 2004
Table 3B-4 RETAIL OUTLET DISTRIBUTION OF ALLERGY RELIEF PRODUCTS, 2003 AND 2004

COLD MEDICATIONS [US$ 425]

Table 3B-5 NEW COLD MEDICATIONS INTRODUCED IN 2003 AND 2004
Table 3B-6 MANUFACTURERS’ SALES OF COLD MEDICATIONS BY BRAND, 2003 AND 2004
Table 3B-7 RETAIL OUTLET DISTRIBUTION OF COLD MEDICATIONS, 2003 AND 2004

COUGH SYRUPS [US$ 350]

Table 3B-8 NEW COUGH SYRUPS INTRODUCED IN 2003 AND 2004
Table 3B-9 MANUFACTURERS’ SALES OF COUGH SYRUPS BY BRAND, 2003 AND 2004
Table 3B-10 RETAIL DISTRIBUTION OF COUGH SYRUPS, 2003 AND 2004

LOZENGES AND DROPS [US$ 350]

Table 3B-11 NEW LOZENGES AND DROPS INTRODUCED IN 2003 AND 2004

Table 3B-12 MANUFACTURERS’ SALES OF LOZENGES AND DROPS BY BRAND, 2003 AND 2004

Table 3B-13 RETAIL OUTLET DISTRIBUTION OF LOZENGES AND DROPS, 2003 AND 2004

NASAL DECONGESTANTS [US$ 250]

Table 3B-14 MANUFACTURERS’ SALES OF NASAL DECONGESTANTS, 2003 AND 2004

Table 3B-15 RETAIL OUTLET DISTRIBUTION OF NASAL DECONGESTANTS, 2003 AND 2004

SINUS REMEDIES [US$ 250]

Table 3B-16 MANUFACTURERS’ SALES OF SINUS REMEDIES, 2003 AND 2004

Table 3B-17 RETAIL OUTLET DISTRIBUTION OF SINUS REMEDIES, 2003 AND 2004

DIGESTIVE PRODUCTS [US$ 1 700]

Table 3C-1 MANUFACTURERS’ SALES OF DIGESTIVE PRODUCTS, 2003 AND 2004
Figure 3C-1 MANUFACTURERS’ SALES OF DIGESTIVE PRODUCTS 2004

ANTACIDS [US$ 600]

Table 3C-2 NEW ANTACIDS INTRODUCED IN 2003 AND 2004

Table 3C-3 MANUFACTURERS’ SALES OF ANTACIDS, 2003 AND 2004

Table 3C-4 RETAIL OUTLET DISTRIBUTION OF ANTACIDS, 2003 AND 2004

ANTIDIARRHEALS [US$ 425]

Table 3C-5 MANUFACTURERS’ SALES OF ANTIDIARRHEALS, 2003 AND 2004

Table 3C-6 RETAIL OUTLET DISTRIBUTION OF ANTIDIARRHEALS, 2003 AND 2004

LAXATIVES [US$ 500]

Table 3C-7 NEW LAXATIVES INTRODUCED IN 2003 AND 2004
Table 3C-8 MANUFACTURERS’ SALES OF LAXATIVES BY BRAND, 2003 AND 2004
Table 3C-9 SALES OF PRIVATE-LABEL LAXATIVES BY SEGMENT, 2003 AND 2004
Table 3C-10 RETAIL OUTLET DISTRIBUTION OF LAXATIVES, 2003 AND 2004

OTHER DIGESTIVE PRODUCTS [US$ 425]

Table 3C-11 NEW OTHER DIGESTIVE PRODUCTS INTRODUCED IN 2003 AND 2004

Table 3C-12 MANUFACTURERS’ SALES OF OTHER DIGESTIVE PRODUCTS, 2003 AND 2004

Table 3C-13 RETAIL OUTLET DISTRIBUTION OF OTHER DIGESTIVE PRODUCTS, 2003 AND 2004

INTERNAL ANALGESICS [US$ 675]

Figure 3D-1 MANUFACTURERS’ SALES OF INTERNAL ANALGESICS, 2004
Table 3D-1 MANUFACTURERS’ SALES OF INTERNAL ANALGESICS, 2003 AND 2004
Table 3D-2 NEW INTERNAL ANALGESICS INTRODUCED IN 2003 AND 2004
Table 3D-3 MANUFACTURERS’ SALES OF INTERNAL ANALGESICS BY BRAND, 2003 AND 2004

NUTRITIONAL PRODUCTS [US$ 1 025]

Table 3E-1 MANUFACTURERS’ SALES NUTRITIONAL PRODUCTS, 2003 AND 2004
Figure 3E-1 MANUFACTURERS’ SALES OF NUTRITIONALS, 2004

DIET AIDS [US$ 300]

Table 3E-2 NEW DIET AIDS INTRODUCED IN 2003 AND 2004

Table 3E 3 MANUFACTURERS’ SALES OF DIET AIDS BY BRAND, 2003 AND 2004

Table 3E-4 RETAIL OUTLET DISTRIBUTION OF DIET AIDS, 2003 AND 2004

HERBAL PRODUCTS [US$ 400]

Table 3E-5 NEW HERBAL PRODUCTS INTRODUCED IN 2003 AND 2004

Table 3E-6 COMMON HERBAL PRODUCTS AND TYPICAL USES

Table 3E-7 MANUFACTURERS’ SALES OF HERBAL PRODUCTS, 2003 AND 2004

Table 3E-8 PRIVATE-LABEL SALES OF HERBAL PRODUCTS, 2003 AND 2004

Table 3E-9 RETAIL OUTLET DISTRIBUTION OF HERBAL PRODUCTS, 2003 AND 2004

VITAMINS AND MINERALS [US$ 400]

Table 3E-10 NEW VITAMINS AND MINERALS INTRODUCED IN 2003 AND 2004

Table 3E-11 MANUFACTURERS’ SALES OF VITAMINS AND MINERALS, 2003 AND 2004

Table 3E-12 MANUFACTURERS’ SALES OF VITAMINS AND MINERALS BY SEGMENT, 2003 AND 2004

Table 3E-13 PRIVATE-LABEL SALES OF VITAMINS AND MINERALS BY SEGMENT, 2003 AND 2004

Table 3E-14 RETAIL OUTLET DISTRIBUTION OF VITAMINS AND MINERALS, 2003 AND 2004

TOPICAL PRODUCTS [US$ 1 700]

Table 3F-1 MANUFACTURERS’ SALES OF TOPICAL PRODUCTS, 2003 AND 2004
Figure 3F-1 MANUFACTURERS’ SALES OF TOPICAL PRODUCTS, 2004

ACNE AIDS [US$ 250]

Table 3F-2 NEW ACNE AIDS INTRODUCED IN 2003 AND 2004

Table 3F-3 MANUFACTURERS’ SALES OF ACNE AIDS BY BRAND, 2003 AND 2004

CONTACT LENS SOLUTIONS [US$ 250]

Table 3F-4 NEW CONTACT LENS SOLUTIONS INTRODUCED IN 2003 AND 2004
Table 3F-5 MANUFACTURERS’ SALES OF CONTACT LENS SOLUTIONS, 2003 AND 2004
Table 3F-6 RETAIL DISTRIBUTION OF CONTACT LENS SOLUTIONS, 2003 AND 2004

DIAPER RASH PRODUCTS [US$ 175]

Table 4F-7 NEW DIAPER RASH PRODUCTS INTRODUCED IN 2003 AND 2004

Table 4F-8 MANUFACTURERS’ SALES OF DIAPER RASH PRODUCTS, 2003 AND 2004

Table 4F-9 RETAIL OUTLET DISTRIBUTION OF DIAPER RASH PRODUCTS, 2003 AND 2004

EYE CARE PRODUCTS [US$ 250]

Table 3F-10 MANUFACTURERS’ SALES OF EYE CARE PRODUCTS BY BRAND, 2003 AND 2004

Table 3F-11 RETAIL OUTLET DISTRIBUTION OF EYE CARE PRODUCTS, 2003 AND 2004

FEMININE YEAST INFECTION REMEDIES [US$ 250]

Table 3F-12 MANUFACTURERS’ SALES OF FEMININE YEAST INFECTION REMEDIES, 2003 AND 2004

Table 3F-13 RETAIL OUTLET DISTRIBUTION OF FEMININE YEAST INFECTION REMEDIES, 2003 AND 2004

FIRST AID PRODUCTS [US$ 250]

Table 3F-14 NEW FIRST AID PRODUCTS INTRODUCED IN 2003 AND 2004

Table 3 15 MANUFACTURERS’ SALES OF FIRST AID PRODUCTS BY BRAND, 2003 AND 2004

Table 3F-16 RETAIL OUTLET DISTRIBUTION OF FIRST AID PRODUCTS, 2003 AND 2004

FOOT CARE PRODUCTS [US$ 250]

Table 3F 17 MANUFACTURERS’ SALES OF FOOT CARE PRODUCTS BY BRAND, 2003 AND 2004

Table 3F-18 RETAIL OUTLET DISTRIBUTION OF FOOT CARE PRODUCTS, 2003 AND 2004

HEMORRHOIDAL PREPARATIONS [US$ 175]

Table 3F-19 MANUFACTURERS’ SALES OF HEMORRHOIDAL PREPARATIONS BY BRAND, 2003 AND 2004

Table 3F-20 RETAIL OUTLET DISTRIBUTION OF HEMORRHOIDAL PREPARATIONS, 2003 AND 2004

TOPICAL ANALGESICS [US$ 175]

Table 3F-21 NEW TOPICAL ANALGESICS INTRODUCED IN 2003 AND 2004

Table 3F 22 MANUFACTURERS’ SALES OF TOPICAL ANALGESICS BY BRAND, 2003 AND 2004

Table 3F-23 RETAIL OUTLET DISTRIBUTION OF TOPICAL ANALGESICS, 2003 AND 2004

MISCELLANEOUS PRODUCTS [US$ 1 025]

Table 3G-1 MANUFACTURERS’ SALES OF MISCELLANEOUS PRODUCTS, 2003 AND 2004
Figure 3G-1 MANUFACTURERS’ SALES OF MISCELLANEOUS PRODUCTS, 2004

HOME DIAGNOSTIC TEST KITS [US$ 525]

Table 3G-2 NEW HOME DIAGNOSTIC TEST KITS INTRODUCED IN 2003 AND 2004

Table 3G-3 MANUFACTURERS’ SALES OF HOME DIAGNOSTIC TEST KITS, 2003 AND 2004

Table 3G-4 RETAIL DISTRIBUTION OF HOME DIAGNOSTIC TEST KITS, 2003 AND 2004

SLEEPING AIDS [US$ 250]

Table 3G-5 MANUFACTURERS’ SALES OF SLEEPING AIDS, 2003 AND 2004

Table 3G-6 RETAIL OUTLET DISTRIBUTION OF SLEEPING AIDS, 2003 AND 2004

SMOKING CESSATION AIDS [US$ 350]

Table 3G-7 NEW SMOKING CESSATION PRODUCTS INTRODUCED IN 2003 AND 2004

Table 3G-8 MANUFACTURERS’ SALES OF SMOKING CESSATION AIDS, 2003 AND 2004

Table 3G-9 RETAIL DISTRIBUTION OF SMOKING CESSATION AIDS, 2003 AND 2004

MAJOR COMPANIES [US$ 6 750]

Table 4 1 LEADING MANUFACTURERS’ SALES OF NONPRESCRIPTION DRUGS, 2004

ABBOTT LABORATORIES [US$ 350]

Table 4-2 ABBOTT LABORATORIES’ SALES OF NONPRESCRIPTION DRUGS, 2003 AND 2004

Table 4 3 FORECAST GROWTH FOR NONPRESCRIPTION DRUGS OF ABBOTT LABORATORIES BY CATEGORY, 2004 TO 2009

BAUSCH & LOMB [US$ 350]

Table 4-4 BAUSCH & LOMB’S SALES OF NONPRESCRIPTION DRUGS, 2003 AND 2004

Table 4 5 FORECAST GROWTH FOR NONPRESCRIPTION DRUGS OF BAUSCH & LOMB BY CATEGORY, 2004 TO 2009

BAYER GROUP [US$ 1 025]

Table 4-6 BAYER GROUP’S SALES OF NONPRESCRIPTION DRUGS, 2003 AND 2004

Table 4-7 NEW PRODUCTS LAUNCHED BY BAYER GROUP, 2003 AND 2004

Table 4 8 FORECAST GROWTH FOR NONPRESCRIPTION DRUGS OF BAYER GROUP BY CATEGORY, 2004 TO 2009

CHURCH & DWIGHT [US$ 675]

Table 4-9 CHURCH & DWIGHT’S SALES OF NONPRESCRIPTION DRUGS, 2003 AND 2004

Table 4-10 NEW PRODUCTS AND LINE EXTENSIONS LAUNCHED BY CHURCH & DWIGHT, 2003 AND 2004

Table 4 11 FORECAST GROWTH FOR NONPRESCRIPTION DRUGS OF CHURCH & DWIGHT BY CATEGORY, 2004 TO 2009

GLAXOSMITHKLINE [US$ 1 025]

Table 4-12 GLAXOSMITHKLINE’S SALES OF NONPRESCRIPTION DRUGS, 2003 AND 2004

Table 4-13 NEW PRODUCTS LAUNCHED BY GLAXOSMITHKLINE, 2003 AND 2004

Table 4 14 FORECAST GROWTH FOR NONPRESCRIPTION DRUGS OF GLAXOSMITHKLINE BY CATEGORY, 2004 TO 2009

JAMIESON LABORATORIES [US$ 350]

Table 4-15 JAMIESON LABORATORIES’ SALES OF NONPRESCRIPTION DRUGS, 2003 AND 2004

Table 4-16 NEW PRODUCTS LAUNCHED BY JAMIESON LABORATORIES, 2003 AND 2004

Table 4 17 FORECAST GROWTH FOR NONPRESCRIPTION DRUGS OF JAMIESON LABORATORIES BY CATEGORY, 2004 TO 2009

JOHNSON & JOHNSON [US$ 1 025]

Table 4-18 JOHNSON & JOHNSON’S SALES OF NONPRESCRIPTION DRUGS, 2003 AND 2004

Table 4-19 NEW PRODUCTS LAUNCHED BY JOHNSON & JOHNSON, 2003 AND 2004

Table 4 20 FORECAST GROWTH FOR NONPRESCRIPTION DRUGS OF JOHNSON & JOHNSON BY CATEGORY, 2004 TO 2009

JOHNSON & JOHNSON-MERCK CONSUMER PHARMACEUTICALS COMPANY [US$ 350]

Table 4-21 JOHNSON & JOHNSON–MERCK’S SALES OF NONPRESCRIPTION DRUGS, 2003 AND 2004

Table 4 22 FORECAST GROWTH FOR NONPRESCRIPTION DRUGS OF JOHNSON & JOHNSON–MERCK BY CATEGORY, 2004 TO 2009

NOVARTIS [US$ 1 025]

Table 4-23 NOVARTIS’S SALES OF NONPRESCRIPTION DRUGS, 2003 AND 2004

Table 4-24 NEW PRODUCTS LAUNCHED BY NOVARTIS, 2003 AND 2004

Table 4-25 FORECAST GROWTH FOR NONPRESCRIPTION DRUGS OF NOVARTIS BY CATEGORY, 2004 TO 2009

PERRIGO [US$ 675]

Table 4-26 PERRIGO’S SALES OF NONPRESCRIPTION DRUGS, 2003 AND 2004

Table 4-27 FORECAST GROWTH FOR NONPRESCRIPTION DRUGS OF PERRIGO BY CATEGORY, 2004 TO 2009

PFIZER [US$ 1 025]

Table 4-28 PFIZER’S SALES OF NONPRESCRIPTION DRUGS, 2003 AND 2004

Table 4-29 NEW PRODUCTS LAUNCHED BY PFIZER, 2003 AND 2004

Table 4-30 FORECAST GROWTH FOR NONPRESCRIPTION DRUGS OF PFIZER BY CATEGORY, 2004 TO 2009

PROCTER & GAMBLE [US$ 350]

Table 4-31 PROCTER & GAMBLE’S SALES OF NONPRESCRIPTION DRUGS, 2003 AND 2004

Table 4-32 FORECAST GROWTH FOR NONPRESCRIPTION DRUGS OF PROCTER & GAMBLE BY CATEGORY, 2004 TO 2009

ROCHE HOLDINGS LTD. [US$ 350]

Table 4-33 ROCHE HOLDINGS’ SALES OF NONPRESCRIPTION DRUGS, 2003 AND 2004

Table 4-34 FORECAST GROWTH FOR NONPRESCRIPTION DRUGS OF ROCHE HOLDINGS BY CATEGORY, 2004 TO 2009

SCHERING-PLOUGH [US$ 675]

Table 4-35 SCHERING-PLOUGH’S SALES OF NONPRESCRIPTION DRUGS, 2003 AND 2004

Table 4-36 NEW PRODUCTS LAUNCHED BY SCHERING-PLOUGH, 2003 AND 2004

Table 4-37 FORECAST GROWTH FOR NONPRESCRIPTION DRUGS OF SCHERING-PLOUGH BY CATEGORY, 2004 TO 2009

WYETH [US$ 675]

Table 4-38 WYETH’S SALES OF NONPRESCRIPTION DRUGS, 2003 AND 2004

Table 4-39 NEW PRODUCTS LAUNCHED BY WYETH, 2003 AND 2004

Table 4 40 FORECAST GROWTH FOR WYETH’S NONPRESCRIPTION DRUGS BY CATEGORY, 2004 TO 2009

MINOR COMPANIES [US$ 4 500]

Table 5-1 ESTIMATED SALES OF NONPRESCRIPTION DRUGS BY 20 MINOR MANUFACTURERS, 2003 AND 2004

INTRODUCTION [US$ 0]

ALCON (NESTLE) [US$ 50]

ADVANCED MEDICAL OPTICS (ALLERGAN) [US$ 50]

AVENTIS [US$ 50]

BOIRON [US$ 50]

BOOTS HEALTHCARE INTERNATIONAL [US$ 50]

BRISTOL-MYERS SQUIBB [US$ 50]

CADBURY SCHWEPPES [US$ 50]

CHATTEM [US$ 50]

COMBE, INC. [US$ 50]

CONTRACT PHARMACEUTICALS LTD. [US$ 50]

DEL LABORATORIES, INC. [US$ 50]

HOLISTA HEALTH [US$ 50]

OTSUKA PHARMACEUTICAL [US$ 50]

PENDOPHARM [US$ 50]

PRESTIGE BRANDS INTERNATIONAL [US$ 50]

THE PURDUE FREDERICK COMPANY, INC. [US$ 50]

RICOLA [US$ 50]

STIEFEL LABORATORIES [US$ 50]

SWISS HERBAL REMEDIES [US$ 50]

WN PHARMACEUTICALS [US$ 50]

MARKET WATCH BULLETIN [US$ 4 500]

COMPANY DEVELOPMENTS [US$ 1 800]

REGULATORY UPDATE [US$ 1 800]

Table 6-1 NONPRESCRIPTION DRUG INGREDIENTS AND THEIR SCHEDULES

Table 6-2 STATUS OF NATIONAL DRUG SCHEDULES HARMONIZATION BY PROVINCE

Table 6-3 RX-TO-OTC SWITCHES IN CANADA, 1985 TO 2004

NEW PRODUCTS [US$ 1 350]

Table 6-4 NEW PRODUCT INTRODUCTIONS IN CANADA, 2003 AND 2004 - SORTED BY CATEGORY

Table 6-5 NEW PRODUCT INTRODUCTIONS IN CANADA, 2003 AND 2004 - SORTED BY COMPANY

STEP 2 of 3

– Provide your contact information:

All fields in *BOLD are required.

*Name:
*Title:
*Company/Division:
*Address 1 :
Address 2 :
*City:
*State/Province:
*Zip/Postal code:
*Country:
*Phone:
Fax:
*Email:

STEP 3 of 3

– Review and accept our subscription terms and conditions by viewing and clicking below:

*Please view our terms and conditions, and check this box to indicate your acceptance of these terms and conditions.

Thank you for your interest in subscribing to our syndicated reports. To complete this process, please click on the button below and a member of our global sales team will contact you shortly to confirm the final price and complete the transaction. Upon acceptance of your order, we will deliver the files in PDF format via email.

Market Research: Nonprescription Drugs Canada 2004

Nonprescription Drugs Canada 2004

ORDER ONLINE

STEP 1 of 3

STEP 2 of 3

STEP 3 of 3

Questions?